Lenvatinib/everolimus improves survival better than everolimus alone in metastatic renal cell cancer
Clinical Advances in Hematology and Oncology H&o 13(8): 512-513
2015
ISSN/ISBN: 1543-0790 PMID: 26351813 Document Number: 684973
Document emailed within 1 workday
Related Documents
Takasaki, S.; Kikuchi, M.; Kawasaki, Y.; Ito, A.; Arai, Y.; Yamaguchi, H.; Mano, N. 2017: A Case of Renal Cell Carcinoma with High Everolimus Blood Concentrations and Hyperglycemia Due to Everolimus-Induced Hepatic Dysfunction Gan to Kagaku Ryoho. Cancer and ChemoTherapy 44(1): 87-89Matsumoto, Y.; Hof, A.; Baumlin, Y.; Müller, M.; Hof, R.P. 2004: Differential effects of everolimus and cyclosporine A on intimal alpha-actin-positive cell dynamics of carotid allografts in mice Transplantation 78(3): 345-351
Flanigan, R.C. 1987: The failure of infarction and/or nephrectomy in stage IV renal cell cancer to influence survival or metastatic regression Urologic Clinics of North America 14(4): 757-762
Badar, Q.; Masood, N.; Abbasi, A.N. 2015: Everolimus induced Pneumonitis Gulf Journal of Oncology 1(18): 18-24
Yazdani, S.K.; Sheehy, A.; Nakano, M.; Nakazawa, G.; Vorpahl, M.; Otsuka, F.; Donn, R.S.; Perkins, L.E.; Simonton, C.A.; Kolodgie, F.D.; Virmani, R. 2013: Preclinical evaluation of second-generation everolimus- and zotarolimus-eluting coronary stents Journal of Invasive Cardiology 25(8): 383-390
Puri, A.; Saireddy, R.; McClean, D. 2013: Simultaneous two-vessel very-late stent thrombosis of everolimus-eluting stents Journal of Invasive Cardiology 25(3): E48-E50
Nakatani, D.; Ako, J.; Yamasaki, M.; Shimohama, T.; Hasegawa, T.; Otake, H.; Waseda, K.; Tsujino, I.; Sakurai, R.; Koo, B.-K.; Chang, H.; Yock, P.G.; Sudhir, K.; Pierson, W.; Stone, G.W.; Saito, S.; Honda, Y.; Fitzgerald, P.J. 2009: Preprocedural inflammation does not affect neointimal hyperplasia following everolimus-eluting stent implantation Journal of Invasive Cardiology 21(12): 613-617
Duman, S.; Bozkurt, D.; Sipahi, S.; Sezak, M.; Ozkan, S.; Ertilav, M.; Sen, S.; Ok, E. 2008: Effects of everolimus as an antiproliferative agent on regression of encapsulating peritoneal sclerosis in a rat model Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis 24: 104-110
Iurin, A.G.; Koval'skiĭ, G.B. 2009: Analysis of survival rates in patients and prognostic models in non-metastatic clear-cell renal cell carcinoma Arkhiv Patologii 71(6): 15-20
Kovarik, J.M.; Kaplan, B.; Tedesco Silva, Hélio.; Kahan, B.D.; Dantal, J.; Vitko, S.; Boger, R.; Rordorf, C. 2002: Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range Transplantation 73(6): 920-925
Robaei, D.; Back, L.; Ooi, S.-Y.; Pitney, M.; Jepson, N. 2016: Twelve-Month Outcomes with a Bioresorbable Everolimus-Eluting Scaffold: Results of the ESHC-BVS Registry at two Australian Centers Journal of Invasive Cardiology 28(8): 316-322
Wernly, B.; Latib, A.; Ielasi, A.; Jung, C. 2019: A Polymeric Bioresorbable Vascular Scaffold Versus an Everolimus-Eluting Stent in ST-Segment Elevation Myocardial Infarction Journal of Invasive Cardiology 31(9): E271-E272
Liang, M.; Liew, T.V.; Puri, A.; Hyde, L.; Devlin, G. 2012: Medium to long-term clinical outcomes with everolimus-eluting stents in real-life percutaneous coronary intervention Annals of the Academy of Medicine Singapore 41(6): 252-257
2016: Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety From a RADIANT-4 Subgroup Analysis Clinical Advances in Hematology and Oncology: H&o 14(5 Suppl. 7): 11-13
Bouzas, L.; Carlos, J. Tutor 2011: Determination of Blood Everolimus Concentrations in Kidney and Liver Transplant Recipients Using the Sirolimus Antibody Conjugated Magnetic Immunoassay (ACMIA) Clinical Laboratory 57(5-6): 403-406
Kaul, U.; Patel, T.M.; Zambahari, R.; Mullasari, A.S.; Bahl, V.K.; Stuteville, M.; Dorange, C.éc.; Veldhof, S.; Grube, E. 2011: Evaluation of the XIENCE V everolimus eluting coronary stent system in the Asian population of the SPIRIT V single arm study. 2-year clinical follow-up data Indian Heart Journal 63(5): 402-408
Berz, D.; Faricy-Anderson, K.E.; Weitzen, S.; Birnbaum, A.; Strauss, G. 2010: Do race and ethnicity predict survival in metastatic non-small cell lung cancer? Medicine and Health Rhode Island 93(10): 299-302
Sternberg, C.N. 2003: Metastatic renal cell cancer treatments Drugs of Today 39 Suppl C: 39-59
Nosov, A.K.; Novik, A.V.; Vorobiev, A.V.; Samartseva, E.E.; Reva, S.A.; Baldueva, I.A.; Lushina, P.A. 2015: Cytoreductive Nephrectomy in Metastatic Renal cell Cancer Voprosy Onkologii 61(3): 494-498
Cokmert, S.; Demir, L.; Can, A.; Akyol, M.; Vedat Bayoglu, I.; Dirican, A.; Kucukzeybek, Y.; Erten, C.; Oktay Tarhan, M. 2014: Capecitabine-related increased mean corpuscular volume of red blood cell may be a predictive marker of treatment response and survival in patients with metastatic colorectal cancer Journal of BUON: Official Journal of the Balkan Union of Oncology 19(1): 75-82